Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $490,000.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 3,500 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total value of $490,000.00. Following the completion of the transaction, the director owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. This represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jazz Pharmaceuticals Trading Up 1.7%

Shares of Jazz Pharmaceuticals stock opened at $139.48 on Monday. The stock has a market cap of $8.46 billion, a P/E ratio of -20.73, a P/E/G ratio of 8.65 and a beta of 0.28. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The business’s 50 day moving average is $123.75 and its 200-day moving average is $115.49.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on JAZZ. Truist Financial boosted their price target on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Morgan Stanley boosted their target price on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Royal Bank Of Canada increased their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a report on Saturday, September 27th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $178.93.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in JAZZ. GAMMA Investing LLC increased its stake in Jazz Pharmaceuticals by 30.7% in the third quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after acquiring an additional 154 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Jazz Pharmaceuticals by 1.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 12,383 shares of the specialty pharmaceutical company’s stock valued at $1,314,000 after acquiring an additional 201 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Jazz Pharmaceuticals by 38.1% during the second quarter. Thrivent Financial for Lutherans now owns 19,720 shares of the specialty pharmaceutical company’s stock worth $2,093,000 after acquiring an additional 5,440 shares in the last quarter. Marex Group plc bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $610,000. Finally, State of Wyoming boosted its stake in shares of Jazz Pharmaceuticals by 21.4% in the 2nd quarter. State of Wyoming now owns 4,029 shares of the specialty pharmaceutical company’s stock valued at $428,000 after purchasing an additional 709 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.